Evidence map›Paper›PMID 28352561›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2017

Synergistic effect of haloduracin and chloramphenicol against clinically important Gram-positive bacteria.

Abolghasem Danesh, Åsa Ljungh, Bo Mattiasson, Gashaw Mamo

Abstract read
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances.International journal of environmental research and public health · 2020
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abolghasem DaneshDepartment of Biotechnology, Lund University, P.O. Box 124, 221 00, Lund, Sweden; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Åsa LjunghDepartment of Medical Microbiology, Lund University, SE-223 62 Lund, Sweden.
Bo MattiassonDepartment of Biotechnology, Lund University, P.O. Box 124, 221 00, Lund, Sweden.
Gashaw MamoDepartment of Biotechnology, Lund University, P.O. Box 124, 221 00, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of drug-resistant pathogens has triggered the search for more efficient antimicrobial agents and formulations for treatment of infections. In recent years, combination therapy has become one of the effective clinical practices in treating infections. The present study deals with the effect of haloduracin, a lantibiotic bateriocin and chloramphenicol against clinically important bacteria. The combined use of haloduracin and chloramphenicol resulted in remarkable synergy against a spectrum of microorganisms including strains of

Indexed as

ChloramphenicolCombination therapyDrug resistanceHaloduracinTopical antibiotics

Identifiers

PMID28352561
PMCPMC5361133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.